TCP11L2

Across TCGA pan-cancer cohorts, TCP11L2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TCP11L2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TCP11L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TCP11L2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where TCP11L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.947	0.467	<.001	27	view →
HNSC	OS	Median	All	1.000	0.377	.022	22	view →
PDAC	DFS	Tertile	III,IV	0.205	0.811	.010	9	view →
LUAD	OS	Quartile	All	0.384	0.828	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TCP11L2–LSCC (DFS)

Open the LSCC breakdown →